Schulman K - Search Results

1

Patterns of bisphosphonate use in the United States in the treatment of metastatic bone disease.

Mortimer JE, Schulman K, Kohles JD. Mortimer JE, et al. Among authors: schulman k. Clin Breast Cancer. 2007 Aug;7(9):682-9. doi: 10.3816/CBC.2007.n.027. Clin Breast Cancer. 2007. PMID: 17919348

2

Economic burden of metastatic bone disease in the U.S.

Schulman KL, Kohles J. Schulman KL, et al. Cancer. 2007 Jun 1;109(11):2334-42. doi: 10.1002/cncr.22678. Cancer. 2007. PMID: 17450591 Free article.

3

Cost comparison of capecitabine in patients with breast cancer.

Rugo HS, Kohles J, Schulman KL. Rugo HS, et al. Am J Clin Oncol. 2010 Dec;33(6):550-6. doi: 10.1097/COC.0b013e3181c06f94. Am J Clin Oncol. 2010. PMID: 20051811

4

Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.

Amin AN, Lin J, Lenhart G, Schulman KL. Amin AN, et al. Thromb Haemost. 2009 Aug;102(2):321-6. doi: 10.1160/TH09-03-0147. Thromb Haemost. 2009. PMID: 19652883

5

Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005.

Peters PH, Moscona A, Schulman KL, Barr CE. Peters PH, et al. Medscape J Med. 2008 Jun 4;10(6):131. Medscape J Med. 2008. PMID: 18679536 Free PMC article.

6

Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer.

Chu E, Schulman KL, Zelt S, Song X. Chu E, et al. Cancer. 2009 Apr 1;115(7):1412-23. doi: 10.1002/cncr.24131. Cancer. 2009. PMID: 19195048 Free article.

7

Burden of illness in Parkinson's disease.

Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Huse DM, et al. Among authors: schulman k. Mov Disord. 2005 Nov;20(11):1449-54. doi: 10.1002/mds.20609. Mov Disord. 2005. PMID: 16007641

8

Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.

Chu E, Schulman KL, McKenna EF Jr, Cartwright T. Chu E, et al. Clin Colorectal Cancer. 2010 Oct;9(4):229-37. doi: 10.3816/CCC.2010.n.034. Clin Colorectal Cancer. 2010. PMID: 20920995

9

A checklist for ascertaining study cohorts in oncology health services research using secondary data: report of the ISPOR oncology good outcomes research practices working group.

Schulman KL, Berenson K, Tina Shih YC, Foley KA, Ganguli A, de Souza J, Yaghmour NA, Shteynshlyuger A. Schulman KL, et al. Value Health. 2013 Jun;16(4):655-69. doi: 10.1016/j.jval.2013.02.006. Epub 2013 May 15. Value Health. 2013. PMID: 23796301 Free article.

10

Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review.

Henry DH, Langer CJ, McKenzie RS, Piech CT, Senbetta M, Schulman KL, Stepanski EJ. Henry DH, et al. Support Care Cancer. 2012 Sep;20(9):2089-96. doi: 10.1007/s00520-011-1318-2. Epub 2011 Dec 11. Support Care Cancer. 2012. PMID: 22160485

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

487 results

Search Page

Filters